Welcome to our dedicated page for Beam Therapeutics news (Ticker: BEAM), a resource for investors and traders seeking the latest updates and insights on Beam Therapeutics stock.
Beam Therapeutics Inc. (Nasdaq: BEAM) generates frequent news as a biotechnology company developing precision genetic medicines through base editing. News about BEAM stock often centers on clinical data readouts, regulatory designations and strategic updates across its hematology and liver-targeted genetic disease franchises.
Investors following BEAM news can expect detailed updates on risto-cel (formerly BEAM-101), an investigational ex vivo base editing cell therapy for sickle cell disease with severe vaso-occlusive crises. The company regularly reports safety and efficacy data from the BEACON Phase 1/2 trial, including measures such as fetal hemoglobin induction, reductions in sickle hemoglobin, engraftment times and markers of hemolysis, as well as designations like RMAT and orphan drug status from the U.S. Food and Drug Administration.
Another major source of headlines is BEAM-302, Beam’s liver-targeting program for alpha-1 antitrypsin deficiency (AATD). Company press releases describe Phase 1/2 trial progress, dose exploration, evidence of in vivo genetic correction of a disease-causing mutation, restoration of functional alpha-1 antitrypsin and regulatory interactions, including RMAT designation, orphan drug designation and participation in the FDA’s CDRP program.
Additional BEAM news items highlight developments in BEAM-301 for glycogen storage disease type Ia, the ESCAPE platform and BEAM-103 antibody, targeted lipid nanoparticle delivery research, financial results, cash runway commentary and participation in scientific and investor conferences. Coverage may also reference Beam’s equity stake in Orbital Therapeutics and the impact of Orbital’s acquisition by Bristol Myers Squibb, as disclosed by the company.
For readers tracking BEAM, this news feed provides ongoing insight into Beam’s clinical milestones, regulatory pathways, platform evolution and corporate transactions that shape the outlook for its precision genetic medicines pipeline.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Beam Therapeutics (Nasdaq: BEAM) announced that CEO John Evans will participate in a fireside chat at the Guggenheim 2023 Genomic Medicines and Rare Disease Day on April 3, 2023, at 10:10 a.m. ET in New York City. The event will feature a live webcast available in the investor section of Beam's website and will be archived for 60 days after the presentation.
Beam Therapeutics focuses on precision genetic medicines through its innovative base editing technology, enabling precise alterations in DNA without double-stranded breaks. The company aims to develop therapies for serious diseases and is committed to advancing its gene editing platform.
Beam Therapeutics (Nasdaq: BEAM) has appointed Dr. Gopi Shanker as its new Chief Scientific Officer (CSO), bringing over 20 years of drug development experience. Dr. Shanker will enhance Beam's base editing programs, a promising technology for genetic medicine that allows precise genome modifications without double-stranded breaks. He previously led efforts at Tevard Biosciences and Novartis, where he oversaw various successful gene therapy programs. This leadership change is expected to strengthen Beam's capabilities in advancing its clinical and preclinical pipeline, aimed at treating genetic diseases, hematology, and oncology.
Beam Therapeutics (Nasdaq: BEAM) will participate in a fireside chat at the Barclays 2023 Global Healthcare Conference on March 16, 2023, at 8:30 a.m. ET in Miami, FL. Dr. Giuseppe Ciaramella, president of Beam, will represent the company. A live webcast will be available on the company’s investor website and archived for 60 days after the event.
Beam specializes in precision genetic medicines through base editing, allowing for efficient single base changes in DNA without double-stranded breaks. The company is focused on developing a fully integrated platform for genetic therapies, aiming to provide life-long cures for serious diseases.
Beam Therapeutics (Nasdaq: BEAM) announced that CEO John Evans will join the "Gene Editing Corporate Panel" at the 43rd Annual Cowen Healthcare Conference on March 8, 2023, at 10:30 a.m. ET in Boston. The event underscores Beam's commitment to developing precision genetic medicines through its proprietary base editing technology, which allows for precise genetic modifications without double-stranded breaks in DNA. A live webcast will be available on the company’s investor website and archived for 60 days. Beam aims to lead in gene editing with a fully integrated platform and values-driven approach focused on lifelong cures for serious diseases.
Beam Therapeutics announced advancements in its pipeline of base editing therapies, with four key development-stage programs. The North Carolina manufacturing facility is set to begin cGMP operations in late 2023. The company closed Q4 2022 with $1.1 billion in cash and equivalents. Beam has initiated clinical development for BEAM-101 and BEAM-201, targeting sickle cell disease and T-cell cancers, while preparing for regulatory filings for BEAM-301 and BEAM-302. The net loss for Q4 2022 was $38.3 million, with the total net loss for 2022 at $289.1 million. Beam's cash reserves are projected to fund operations into 2025.
Beam Therapeutics, a leader in precision genetic medicines, announced that CEO John Evans will speak at the SVB Securities Virtual Global Biopharma Conference on February 14, 2023, at 8:40 a.m. ET. The event will be accessible via a live webcast on the company's investor website, and it will remain archived for 60 days. Beam is focused on advancing its proprietary base editing technology, aimed at enabling precise gene modifications without DNA breaks. This platform supports a diverse portfolio of therapeutic editing strategies to treat serious diseases, showcasing the company's commitment to innovative science and patient solutions.